Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free CDTTW Stock Alerts

Conduit Pharmaceuticals (CDTTW) Financials

$0.01 0.00 (-26.67%)
As of 07/22/2026 02:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Conduit Pharmaceuticals

Annual Income Statements for Conduit Pharmaceuticals

This table shows Conduit Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -4.89 -0.80 -18 -40
Consolidated Net Income / (Loss)		 -4.89 -0.54 -18 -39
Net Income / (Loss) Continuing Operations		 -4.89 -0.54 -18 -39
Total Pre-Tax Income 		-4.89 -0.54 -18 -39
Total Operating Income		 -3.16 -5.26 -15 -37
Total Gross Profit		 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00
Total Operating Expenses		 3.16 5.26 15 37
Selling, General & Admin Expense		 3.05 5.17 12 32
Research & Development Expense		 0.04 0.09 3.38 5.05
Total Other Income / (Expense), net		 -1.73 4.73 -2.38 -2.47
Interest & Investment Income		 0.00 -0.20 -1.49 -0.29
Other Income / (Expense), net		 -1.73 4.92 -0.89 -2.18
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - 0.26 -0.00 0.43
Basic Earnings per Share		 ($0.13) ($0.79) ($61,598.62) ($1,177.89)
Weighted Average Basic Shares Outstanding		 37.45M 669.74K 289.00 33.30K
Diluted Earnings per Share		 ($0.13) ($8.92) ($61,598.62) ($1,177.89)
Weighted Average Diluted Shares Outstanding		 37.45M 678.94K 289.00 33.30K

Quarterly Income Statements for Conduit Pharmaceuticals

This table shows Conduit Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 3.24 -0.63 -3.58 -5.38 -6.58 -2.26 -4.82 -6.11 -7.17 -22 -3.82
Consolidated Net Income / (Loss)		 2.63 0.25 -3.55 -5.38 -6.46 -2.41 -4.75 -6.03 -7.12 -21 -4.06
Net Income / (Loss) Continuing Operations		 2.63 0.25 -3.55 -5.38 -6.46 -2.41 -4.75 -6.03 -7.12 -21 -4.06
Total Pre-Tax Income 		2.63 0.25 -3.55 -5.38 -6.46 -2.41 -4.75 -6.03 -7.12 -21 -4.06
Total Operating Income		 -0.43 -2.43 -2.96 -3.14 -5.81 -3.51 -3.62 -4.95 -7.03 -21 -3.66
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 0.43 2.43 2.96 3.14 5.81 3.51 3.62 4.95 7.03 21 3.66
Selling, General & Admin Expense		 0.43 2.34 2.83 3.12 2.72 3.38 2.70 3.09 5.50 20 2.88
Research & Development Expense		 0.00 0.09 0.13 0.03 3.09 0.13 0.92 1.86 1.53 0.75 0.78
Total Other Income / (Expense), net		 3.06 2.67 -0.60 -2.24 -0.65 1.11 -1.14 -1.08 -0.09 -0.17 -0.41
Interest & Investment Income		 0.00 -0.20 -0.11 -0.12 -0.31 -0.96 -0.17 -0.05 -0.04 -0.03 -0.12
Other Income / (Expense), net		 3.10 2.82 -0.49 -2.13 -0.34 2.06 -0.97 -1.02 -0.04 -0.14 -0.29
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - 0.02 0.00 0.12 -0.14 0.07 0.08 0.05 0.23 -0.25
Basic Earnings per Share		 $0.04 ($0.94) ($4.81) ($109.33) ($889.58) ($7,830.45) ($3,670.27) ($5.46) ($13.16) ($647.39) ($5.56)
Weighted Average Basic Shares Outstanding		 65.41M 669.74K 738.30K 49.23K 7.26K 289.00 1.30K 1.10M 540.84K 33.30K 730.46K
Diluted Earnings per Share		 $0.01 ($0.94) ($4.81) ($109.33) ($889.58) ($7,830.45) ($3,670.27) ($5.46) ($13.16) ($647.39) ($5.56)
Weighted Average Diluted Shares Outstanding		 66.13M 678.94K 738.30K 49.23K 7.26K 289.00 1.30K 1.10M 540.84K 33.30K 730.46K

Annual Cash Flow Statements for Conduit Pharmaceuticals

This table details how cash moves in and out of Conduit Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.00 4.23 -3.66 0.96
Net Cash From Operating Activities		 -2.27 -7.73 -9.68 -16
Net Cash From Continuing Operating Activities		 -2.27 -7.73 -9.68 -15
Net Income / (Loss) Continuing Operations		 -4.89 -0.54 -18 -39
Consolidated Net Income / (Loss)		 -4.89 -0.54 -18 -39
Depreciation Expense		 - 0.00 0.01 0.02
Amortization Expense		 0.00 0.48 3.04 3.84
Non-Cash Adjustments To Reconcile Net Income		 2.02 -5.15 5.09 15
Changes in Operating Assets and Liabilities, net		 0.60 -2.52 -0.02 4.73
Net Cash From Investing Activities		 -0.18 0.73 -0.04 -0.81
Net Cash From Continuing Investing Activities		 -0.18 0.73 -0.04 -0.81
Purchase of Property, Plant & Equipment		 - 0.00 -0.05 -0.41
Purchase of Investments		 -0.33 -0.36 -0.49 0.00
Sale and/or Maturity of Investments		 - 0.00 0.50 0.00
Other Investing Activities, net		 0.15 1.08 0.00 -0.40
Net Cash From Financing Activities		 2.45 11 6.07 17
Net Cash From Continuing Financing Activities		 2.45 11 6.07 17
Repayment of Debt		 - 0.00 -0.78 -2.17
Repurchase of Common Equity		 - - 0.00 -0.11
Issuance of Debt		 1.11 2.29 3.23 0.00
Issuance of Common Equity		 1.34 0.00 3.44 20
Other Financing Activities, net		 0.00 8.64 0.18 0.00
Effect of Exchange Rate Changes		 0.00 0.30 - -0.10
Cash Interest Paid		 - 0.12 0.08 0.00

Quarterly Cash Flow Statements for Conduit Pharmaceuticals

This table details how cash moves in and out of Conduit Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 8.64 -4.42 -2.38 -1.63 -0.15 0.50 1.58 1.20 0.51 -2.33 -1.41
Net Cash From Operating Activities		 -0.52 -4.80 -2.36 -1.51 -2.00 -3.81 -3.93 -2.18 -4.41 -4.64 -1.89
Net Cash From Continuing Operating Activities		 -0.52 -4.80 -2.36 -1.51 -2.00 -3.81 -3.93 -2.18 -4.41 -4.53 -1.89
Net Income / (Loss) Continuing Operations		 2.63 0.25 -3.55 -5.38 -6.46 -2.41 -4.75 -5.64 -7.12 -21 -4.06
Consolidated Net Income / (Loss)		 2.63 0.25 -3.55 -5.38 -6.46 -2.41 -4.75 -5.64 -7.12 -21 -4.06
Depreciation Expense		 - - 0.00 - 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Amortization Expense		 0.04 0.44 0.42 0.44 0.58 1.60 0.56 1.20 1.27 0.82 0.85
Non-Cash Adjustments To Reconcile Net Income		 -3.64 -2.79 0.97 2.82 2.02 -0.72 1.47 1.27 1.78 11 1.16
Changes in Operating Assets and Liabilities, net		 0.45 -2.69 -0.20 0.61 1.86 -2.29 -1.21 0.98 -0.34 5.30 0.15
Net Cash From Investing Activities		 0.07 0.50 0.00 -0.22 0.10 0.09 -0.40 -0.40 -1.00 0.60 0.00
Net Cash From Continuing Investing Activities		 0.07 0.50 0.00 -0.22 0.10 0.09 -0.40 -0.40 -1.00 0.60 0.00
Purchase of Property, Plant & Equipment		 - - 0.00 -0.01 -0.04 - -0.40 -0.40 0.01 -0.01 0.00
Net Cash From Financing Activities		 9.11 -0.41 0.00 0.11 1.74 4.21 5.93 3.76 6.00 1.74 0.49
Net Cash From Continuing Financing Activities		 9.11 -0.41 0.00 0.11 1.74 4.21 5.93 3.76 6.00 1.74 0.49
Repayment of Debt		 - - 0.00 - 0.12 -0.89 -2.13 -0.02 -0.01 -0.00 0.00
Issuance of Debt		 0.55 -0.49 - - - 1.60 0.00 - - - 0.49
Issuance of Common Equity		 0.15 -0.15 0.00 0.11 0.00 3.33 8.06 3.89 6.01 1.74 0.00
Effect of Exchange Rate Changes		 -0.01 0.30 -0.03 -0.00 0.01 - -0.02 0.03 -0.08 -0.03 -0.01
Cash Interest Paid		 - 0.12 0.08 - - - 0.17 -0.17 - - 0.00
Cash Income Taxes Paid		 - - - - - - 0.00 - - - 0.00

Annual Balance Sheets for Conduit Pharmaceuticals

This table presents Conduit Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.21 0.01 7.22 4.19 5.65
Total Current Assets		 0.10 0.00 5.73 2.72 4.38
Cash & Equivalents		 0.05 0.00 4.23 0.55 1.51
Prepaid Expenses		 0.06 0.00 1.51 2.16 2.87
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.04 0.27
Total Noncurrent Assets		 0.11 0.01 1.49 1.44 1.00
Long-Term Investments		 - - - - 0.00
Other Noncurrent Operating Assets		 0.11 0.00 1.49 1.44 1.00
Total Liabilities & Shareholders' Equity		 0.21 0.01 7.22 4.19 5.65
Total Liabilities		 0.19 10 7.68 11 13
Total Current Liabilities		 0.19 4.18 1.80 11 13
Short-Term Debt		 0.18 0.18 0.19 0.58 0.00
Accounts Payable		 - 0.00 0.22 1.43 1.91
Accrued Expenses		 0.02 2.25 0.60 1.96 10
Other Current Liabilities		 - 1.42 0.80 6.78 0.78
Total Noncurrent Liabilities		 0.00 5.92 5.88 0.25 0.00
Commitments & Contingencies		 0.00 - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.02 -10 -0.46 -6.79 -7.17
Total Preferred & Common Equity		 0.02 -10 -0.46 -6.79 -7.17
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 0.02 -10 -0.46 -6.79 -7.17
Common Stock		 0.03 0.01 10 22 61
Retained Earnings		 -0.00 -11 -11 -29 -68
Accumulated Other Comprehensive Income / (Loss)		 - 0.68 0.41 0.41 -0.02

Quarterly Balance Sheets for Conduit Pharmaceuticals

This table presents Conduit Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 12 4.92 3.31 2.99 7.71 7.99 8.55 127
Total Current Assets		 10 3.16 1.60 1.40 5.95 6.39 7.09 3.05
Cash & Equivalents		 8.64 1.84 0.22 0.07 2.13 3.33 3.84 0.10
Prepaid Expenses		 1.80 1.31 1.17 1.25 3.82 3.05 2.27 2.96
Plant, Property, & Equipment, net		 0.00 0.00 0.05 0.05 0.43 0.38 0.33 0.21
Total Noncurrent Assets		 1.58 1.76 1.65 1.55 1.33 1.22 1.13 124
Long-Term Investments		 - - - - - - - 123
Other Noncurrent Operating Assets		 1.57 1.76 1.65 1.55 1.33 1.22 1.13 0.89
Total Liabilities & Shareholders' Equity		 12 4.92 3.31 2.99 7.71 7.99 8.55 127
Total Liabilities		 13 8.02 8.77 12 4.63 4.46 4.27 22
Total Current Liabilities		 4.60 7.72 8.59 12 4.55 4.41 4.27 22
Short-Term Debt		 0.18 0.18 0.18 1.49 0.00 0.00 0.00 0.00
Accounts Payable		 0.04 0.12 1.06 1.90 0.71 1.25 0.61 2.42
Accrued Expenses		 2.81 0.74 0.67 1.79 1.05 1.14 1.79 10
Other Current Liabilities		 1.55 0.94 0.94 1.07 2.79 2.02 1.87 8.85
Total Noncurrent Liabilities		 8.50 0.29 0.17 0.13 0.09 0.05 0.01 0.00
Commitments & Contingencies		 - - - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -1.08 -3.10 -5.46 -9.12 3.08 3.53 4.28 105
Total Preferred & Common Equity		 -1.08 -3.10 -5.46 -9.12 3.08 3.53 4.28 105
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -1.08 -3.10 -5.46 -9.12 3.08 3.53 4.28 105
Common Stock		 11 11 14 17 37 43 51 178
Retained Earnings		 -13 -15 -20 -27 -34 -40 -47 -72
Accumulated Other Comprehensive Income / (Loss)		 0.64 0.39 0.39 0.27 0.35 0.27 0.22 0.23

Annual Metrics And Ratios for Conduit Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Conduit Pharmaceuticals' official financial filings.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 17,285,250.00 145,627,552.00 102,847,973.00 1,629,402.00
DEI Adjusted Shares Outstanding		 1,440.00 12,136.00 14.00 2,607.00
DEI Earnings Per Adjusted Shares Outstanding		 -3,393.75 -65.84 -1,271,357.14 -15,210.59
Growth Metrics		 - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% 102.86% -9,569.29% -164.52%
EBIT Growth		 0.00% 93.06% -4,710.91% -138.72%
NOPAT Growth		 0.00% -66.52% -193.03% -138.39%
Net Income Growth		 0.00% 89.05% -3,227.48% -120.33%
EPS Growth		 0.00% 89.05% -3,227.48% -120.33%
Operating Cash Flow Growth		 0.00% -240.91% -25.33% -60.66%
Free Cash Flow Firm Growth		 0.00% 0.00% -17.33% -179.57%
Invested Capital Growth		 0.00% 44.30% -50.49% -28.16%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 103.13% -5.33% -142.85%
EBIT Q/Q Growth		 0.00% 92.49% -12.74% -103.99%
NOPAT Q/Q Growth		 0.00% -16.50% -7.56% -92.30%
Net Income Q/Q Growth		 0.00% 87.67% -17.50% -93.17%
EPS Q/Q Growth		 0.00% 0.00% -17.50% -93.17%
Operating Cash Flow Q/Q Growth		 0.00% -103.18% 9.28% -5.59%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 27.81% -10.30%
Invested Capital Q/Q Growth		 0.00% 52.87% 12.95% -2,072.50%
Profitability Metrics		 - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 157.82% 109.15% 100.75%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 97.08% 10.15% 491.09% 561.83%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 97.08% 10.15% 491.09% 561.83%
Return on Equity Simple (ROE_SIMPLE)		 48.44% 117.07% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.21 -3.68 -11 -26
NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 133.08% 309.73% -348.52% -1,813.72%
Return On Investment Capital (ROIC_SIMPLE)		 - 1,354.19% 173.58% 358.86%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.89 -0.34 -16 -39
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.89 0.14 -13 -35
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 2,337.57 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 -0.20 -0.40 -0.08 0.00
Long-Term Debt to Equity		 -0.18 0.00 0.00 0.00
Financial Leverage		 -0.20 0.19 0.55 0.11
Leverage Ratio		 -0.02 -0.69 -1.57 -0.70
Compound Leverage Factor		 -0.02 -1.08 -1.72 -0.71
Debt to Total Capital		 -24.88% -68.01% -9.25% 0.00%
Short-Term Debt to Total Capital		 -2.17% -68.01% -9.25% 0.00%
Long-Term Debt to Total Capital		 -22.71% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 124.88% 168.01% 109.25% 100.00%
Debt to EBITDA		 -0.41 1.32 -0.04 0.00
Net Debt to EBITDA		 -0.41 -28.88 0.00 0.00
Long-Term Debt to EBITDA		 -0.38 0.00 0.00 0.00
Debt to NOPAT		 -0.91 -0.05 -0.05 0.00
Net Debt to NOPAT		 -0.91 1.10 0.00 0.00
Long-Term Debt to NOPAT		 -0.83 0.00 0.00 0.00
Altman Z-Score		 0.00 24.19 -24.46 -41.36
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - -
Current Ratio		 0.00 3.18 0.25 0.34
Quick Ratio		 0.00 2.35 0.05 0.12
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -7.26 -8.52 -24
Operating Cash Flow to CapEx		 0.00% 0.00% -18,984.31% -3,840.74%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - -
Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - -
Invested Capital		 -8.08 -4.50 -6.77 -8.68
Invested Capital Turnover		 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 3.58 -2.27 -1.91
Enterprise Value (EV)		 0.00 327 7.08 0.58
Market Capitalization		 0.00 331 7.06 2.09
Book Value per Share		 ($0.58) ($0.01) ($0.07) ($4.40)
Tangible Book Value per Share		 ($0.58) ($0.01) ($0.07) ($4.40)
Total Capital		 -8.08 -0.27 -6.22 -7.17
Total Debt		 2.01 0.19 0.58 0.00
Total Long-Term Debt		 1.84 0.00 0.00 0.00
Net Debt		 2.01 -4.04 0.02 -1.51
Capital Expenditures (CapEx)		 0.00 0.00 0.05 0.41
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.00 -0.11 -8.01 -9.95
Debt-free Net Working Capital (DFNWC)		 -4.00 4.12 -7.45 -8.44
Net Working Capital (NWC)		 -4.18 3.93 -8.03 -8.44
Net Nonoperating Expense (NNE)		 2.68 -3.15 7.01 13
Net Nonoperating Obligations (NNO)		 2.01 -4.04 0.02 -1.51
Total Depreciation and Amortization (D&A)		 0.00 0.48 3.05 3.87
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.00) ($1,539,750.00) ($1,177.89)
Adjusted Weighted Average Basic Shares Outstanding		 15.86M 669.74K 12.00 33.30K
Adjusted Diluted Earnings per Share		 $0.00 ($9.00) ($1,539,750.00) ($1,177.89)
Adjusted Weighted Average Diluted Shares Outstanding		 6.25M 678.94K 12.00 33.30K
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 6.25M 0.00 89.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -2.21 -3.68 -11 -26
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -0.27%

Quarterly Metrics And Ratios for Conduit Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Conduit Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 6,247,978.00 145,627,552.00 145,627,552.00 147,659,072.00 192,009,398.00 102,847,973.00 6,662,755.00 23,922,920.00 3,062,025.00 1,629,402.00 1,629,402.00
DEI Adjusted Shares Outstanding		 521.00 12,136.00 12,136.00 12,305.00 16,001.00 14.00 89.00 199,358.00 382,753.00 2,607.00 2,607.00
DEI Earnings Per Adjusted Shares Outstanding		 6,209.21 -51.83 -294.58 -437.55 -411.04 -161,642.86 -54,168.54 -30.62 -18.73 -8,269.28 -1,463.75
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 384.10% 149.23% -80.62% -178.42% -305.08% -80.94% -33.08% 1.14% -4.17% -13,055.70% 23.21%
EBIT Growth		 379.50% 123.40% -105.86% -203.87% -330.24% -467.77% -33.21% -13.46% -15.04% -1,369.70% 13.94%
NOPAT Growth		 34.16% -106.07% -95.05% -253.60% -845.98% -1.24% -22.37% -57.71% -21.03% -502.22% -1.11%
Net Income Growth		 374.58% 106.88% -112.44% -210.62% -346.13% -1,082.04% -33.81% -11.98% -10.17% -786.33% 14.52%
EPS Growth		 133.33% 0.00% -112.44% -210.62% -346.13% -1,082.04% -33.81% 95.01% -10.17% -786.33% 99.85%
Operating Cash Flow Growth		 7.52% -445.80% -19.64% -253.50% -281.49% 20.61% -66.70% -44.08% -120.61% -21.58% 51.79%
Free Cash Flow Firm Growth		 0.00% 0.00% -81.92% -81.35% -104.16% 96.89% -140.63% -144.59% -125.16% -6,795.88% 293.77%
Invested Capital Growth		 -107.28% 44.30% -127.06% -132.62% 18.53% -50.49% 119.96% 103.45% 105.66% -28.16% -1,950.32%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 256.72% -69.48% -464.29% -59.77% -15.44% 102.84% -2,643.67% -7.94% -21.64% -252.81% 84.92%
EBIT Q/Q Growth		 254.18% -85.25% -973.60% -52.99% -16.82% 76.45% -216.43% -20.03% -18.44% -200.92% 81.47%
NOPAT Q/Q Growth		 30.82% -464.88% 14.84% -6.26% -85.06% 39.55% -2.93% -23.52% -42.02% -200.81% 82.72%
Net Income Q/Q Growth		 251.47% -90.67% -1,549.80% -51.55% -20.03% 62.76% -97.55% -17.14% -18.08% -199.59% 80.95%
EPS Q/Q Growth		 150.00% -90.67% -1,549.80% -51.55% -20.03% 62.76% -97.55% -313.64% -18.08% -199.59% 99.14%
Operating Cash Flow Q/Q Growth		 -22.43% -816.60% 50.93% 35.81% -32.12% -90.75% -3.04% 49.64% -102.29% -5.12% 59.15%
Free Cash Flow Firm Q/Q Growth		 24.45% -104.28% 437.60% 3.66% -127.76% 96.79% -4,304.70% -15.41% -40.18% 1.83% 223.77%
Invested Capital Q/Q Growth		 -154.53% 52.87% -5.78% -20.00% -36.19% 12.95% 114.03% -64.63% 123.35% -2,072.50% -102.53%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 98.24% 62.18% 103.20% 102.22% 105.02% 166.05% 103.66% 100.89% 100.58% 100.14% 102.97%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -6.63% 10.15% -33.82% -104.78% 297.11% 491.09% 200,031.58% 2,073.56% 839.05% 561.83% -71.01%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,785.89% -9,496.70% -4,908.82% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.24% 10.15% 20.31% 104.38% 297.11% 491.09% 200,031.58% 2,073.56% 839.05% 561.83% -71.01%
Return on Equity Simple (ROE_SIMPLE)		 401.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.43 -2.43 -2.07 -2.20 -4.07 -2.46 -2.53 -3.47 -4.92 -15 -2.56
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 66.45% 263.06% -204.39% 2,866.28% -67.15% 2.64% -117.21% -143.03% -175.66% -875.78% -2.40%
Return On Investment Capital (ROIC_SIMPLE)		 - 893.01% 70.94% 41.64% 53.33% 39.55% -82.18% -98.23% -115.08% 206.54% -2.43%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 2.67 0.39 -3.44 -5.27 -6.15 -1.45 -4.59 -5.98 -7.08 -21 -3.95
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 2.72 0.83 -3.02 -4.83 -5.57 0.16 -4.02 -4.77 -5.80 -20 -3.09
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 1.69 0.62 0.49 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 1.69 0.62 0.49 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 3.24 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 2,337.57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 15.04 4.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -0.16 -0.40 -0.06 -0.03 -0.16 -0.08 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.07 0.19 -0.10 0.02 0.70 0.55 199.53 1.85 0.52 0.11 -1.15
Leverage Ratio		 1.14 -0.69 2.02 2.33 -1.47 -1.57 -664.79 -5.84 -2.39 -0.70 1.24
Compound Leverage Factor		 1.12 -0.43 2.09 2.38 -1.55 -2.61 -689.15 -5.89 -2.40 -0.71 1.28
Debt to Total Capital		 -19.58% -68.01% -6.28% -3.47% -19.55% -9.25% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 -19.58% -68.01% -6.28% -3.47% -19.55% -9.25% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 119.58% 168.01% 106.28% 103.47% 119.55% 109.25% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.04 1.32 -0.15 -0.04 -0.12 -0.04 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 1.89 -28.88 1.38 0.06 -0.11 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.06 -0.05 -0.04 -0.03 -0.15 -0.05 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 2.68 1.10 0.35 0.04 -0.13 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 24.52 12.35 -11.01 -22.95 -12.77 -7.21 -8.86 -9.74 -31.06 -1.08
Noncontrolling Interest Sharing Ratio		 103.65% 0.00% 160.06% 199.62% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.27 3.18 0.41 0.19 0.12 0.25 1.31 1.45 1.66 0.34 0.14
Quick Ratio		 1.88 2.35 0.24 0.05 0.01 0.05 0.47 0.76 0.90 0.12 0.00
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 140 -6.01 20 21 -5.84 -0.19 -8.24 -9.38 -13 -13 16
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% -15,130.00% -4,875.61% 0.00% -972.52% -543.64% 0.00% -66,228.57% 0.00%
Free Cash Flow to Firm to Interest Expense		 2,985.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -11.15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -11.15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -9.55 -4.50 -4.76 -5.71 -7.78 -6.77 0.95 0.20 0.44 -8.68 -18
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -141 3.58 -22 -23 1.77 -2.27 5.71 5.91 8.22 -1.91 -19
Enterprise Value (EV)		 0.00 327 266 78 13 7.08 3.07 -1.13 -1.76 0.58 -123
Market Capitalization		 0.00 331 267 78 11 7.06 5.20 2.20 2.08 2.09 0.01
Book Value per Share		 ($0.17) ($0.01) ($0.04) ($0.07) ($0.10) ($0.07) $0.46 $0.30 $1.40 ($4.40) $64.72
Tangible Book Value per Share		 ($0.17) ($0.01) ($0.04) ($0.07) ($0.10) ($0.07) $0.46 $0.30 $1.40 ($4.40) $64.72
Total Capital		 -0.90 -0.27 -2.92 -5.28 -7.63 -6.22 3.08 3.53 4.28 -7.17 105
Total Debt		 0.18 0.19 0.18 0.18 1.49 0.58 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -8.47 -4.04 -1.66 -0.25 1.34 0.02 -2.13 -3.33 -3.84 -1.51 -123
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.01 0.04 0.00 0.40 0.40 -0.01 0.01 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.63 -0.11 -6.23 -7.24 -9.24 -8.01 -0.73 -1.36 -1.01 -9.95 -19
Debt-free Net Working Capital (DFNWC)		 6.02 4.12 -4.38 -6.81 -9.09 -7.45 1.40 1.97 2.83 -8.44 -19
Net Working Capital (NWC)		 5.84 3.93 -4.57 -6.99 -11 -8.03 1.40 1.97 2.83 -8.44 -19
Net Nonoperating Expense (NNE)		 -3.06 -2.67 1.48 3.19 2.39 -0.05 2.22 2.56 2.19 6.52 1.50
Net Nonoperating Obligations (NNO)		 -8.47 -4.04 -1.66 -0.25 1.34 0.02 -2.13 -3.33 -3.84 -1.51 -123
Total Depreciation and Amortization (D&A)		 0.04 0.44 0.42 0.44 0.58 1.61 0.57 1.21 1.28 0.83 0.86
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($94.00) $0.00 $0.00 ($840.00) ($58,728,375,000.00) $0.00 ($5.46) ($13.16) ($404,618.75) ($5.56)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 6.70K 0.00 0.00 7.26K 0.00 0.00 1.10M 540.84K 53.00 730.46K
Adjusted Diluted Earnings per Share		 $0.00 ($94.00) $0.00 $0.00 ($840.00) ($58,728,375,000.00) $0.00 ($5.46) ($13.16) ($404,618.75) ($5.56)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 6.79K 0.00 0.00 7.26K 0.00 0.00 1.10M 540.84K 53.00 730.46K
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($94.00) $0.00 $0.00 $0.00 ($58,728,375,000.00) $0.00 $0.00 $0.00 ($404,618.75) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 8.57K 1.00 0.00 3.06M 1.63M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -0.30 -1.70 -2.07 -2.20 -4.07 -2.46 -2.53 -3.47 -4.92 -15 -2.56
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 56.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -9.15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 56.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -9.15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.27% 0.00%

Financials Breakdown Chart

Key Financial Trends

Conduit Pharmaceuticals (NASDAQ: CDT) continues to look like a pre-revenue, cash-burning biotech with no operating revenue and persistent net losses. The latest quarter shows another period of heavy spending, negative operating cash flow, and reliance on financing to stay funded.

  • Cash and equivalents rose sharply from $3.8 million at Q3 2025 to $97,000 in Q1 2026 after a large cash usage period, but the company still retained a very large pool of long-term investments at $122.9 million.
  • The balance sheet at Q1 2026 shows $127.1 million in total assets, which is substantial relative to the company’s operating scale.
  • The company had no short-term debt at Q1 2026, which reduces immediate refinancing risk.
  • Quarterly operating cash burn improved versus the prior quarter: net cash from operations was -$1.9 million in Q1 2026, compared with -$4.6 million in Q4 2025 and -$4.4 million in Q3 2025.
  • Operating expenses also came down materially in Q1 2026 to $3.7 million from $21.2 million in Q4 2025, reflecting a much lower cost base.
  • Shares outstanding were far lower in Q1 2026 than in some prior periods, suggesting a cleaner capital structure than the extremely inflated share counts seen earlier in the history provided.
  • Q1 2026 reported no revenue, so the business is still entirely dependent on financing and asset monetization rather than commercial sales.
  • The company recorded no capital expenditures in Q1 2026, so near-term cash needs for fixed assets appear minimal.
  • Other income and investment-related items remain volatile across quarters, making reported earnings less predictable.
  • The company posted a net loss of $4.1 million in Q1 2026, and losses have been persistent for several years.
  • Operating cash flow remained negative at -$1.9 million in Q1 2026, which means the core business is still consuming cash.
  • Liquidity looks much tighter than in prior periods: cash fell from $3.8 million in Q3 2025 to just $97,000 in Q1 2026.
  • Current liabilities were $21.6 million versus only $3.1 million in current assets in Q1 2026, creating a working-capital deficit.
  • Retained earnings remain deeply negative at -$72.4 million, reflecting years of accumulated losses.
  • The company has shown repeated dependence on financing, including equity and debt proceeds in prior quarters, which could mean further dilution or financing risk ahead.

Bottom line: CDT’s latest quarter shows some improvement in expense control and operating cash burn, but the company still has no revenue, ongoing losses, and a weak working-capital position. Investors should view the name as highly speculative and financing-dependent.

07/23/26 01:22 AM ETAI Generated. May Contain Errors.

Conduit Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Conduit Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Conduit Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$39.22 million in 2025, rising from -$4.89 million in 2022. The previous period was -$17.80 million in 2024.

Conduit Pharmaceuticals' total operating income in 2025 was -$36.76 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $36.76 million

Over the last 3 years, Conduit Pharmaceuticals' total revenue changed from $0.00 in 2022 to $0.00 in 2025, a change of 0.0%.

Conduit Pharmaceuticals' total liabilities were at $12.82 million at the end of 2025, a 16.7% increase from 2024, and a 6,559.5% increase since 2021.

In the past 4 years, Conduit Pharmaceuticals' cash and equivalents has ranged from $0.00 in 2022 to $4.23 million in 2023, and is currently $1.51 million as of their latest financial filing in 2025.

Over the last 3 years, Conduit Pharmaceuticals' book value per share changed from -0.58 in 2022 to -4.40 in 2025, a change of 653.9%.


Related Companies

Financial statements for NASDAQ:CDTTW last updated on 7/20/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel